HeartSciences shares rise 11.11% after-hours as Ascendiant Capital raises price target to $9.20 with Buy rating.

HeartSciences surged 11.11% in after-hours trading following Ascendiant Capital analyst Lucas Ward’s decision to maintain a Buy rating on the stock and raise the price target from $9 to $9.2. The upward revision in the price target signals increased confidence in the company’s prospects, likely prompting investor optimism and post-market buying activity. The move aligns with the firm’s positive assessment of HeartSciences’ value proposition, reinforcing its strategic positioning in the market.